Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...

The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

If this CEO succeeds N-Power could save millions of dollars and lives in the fight against cancer. "The impact for cancer ...

Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

Discover Zealand Pharma's Q4 2024 earning highlights, key obesity pipeline advancements, and future plans for petrelintide and dapiglutide.

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...

Key achievements included positive Phase 3 ASPEN data for brensocatib in bronchiectasis, record-breaking ARIKAYCE revenues, and advancements in other pipeline programs such as TPIP and ARIKAYCE's ...

Objective This study aims to calculate the global warming potential, in carbon dioxide (CO 2) equivalent emissions, from all in-scope activities involved in phase 1, 2, 3 and 4 clinical trials ...

Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...